Author

M. Foglierini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Cassotta· 2 shared A. Ceschi· 2 shared A. Lanzavecchia· 2 shared C. Garzoni· 2 shared D. Jarrossay· 2 shared F. Mele· 2 shared F. Sallusto· 2 shared J. S. Low· 2 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Cassotta

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

J. S. Low, J. Jerak, M. A. Tortorici, M. McCallum, D. Pinto, A. Cassotta, M. Foglierini, F. Mele, R. Abdelnabi, B. Weynand, J. Noack, M. Montiel-Ruiz, S. Bianchi, F. Benigni, N. Sprugasci, , F. Sallusto

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

bioRxiv · Mar 30, 2022Immunology

Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

J. S. Low, D. Vaqueirinho, F. Mele, M. Foglierini, M. Perotti, D. Jarrossay, S. Jovic, T. Terrot, A. Franzetti Pellanda, M. Biggiogero, C. Garzoni, P. Ferrari, A. Ceschi, A. Lanzavecchia, A. Cassotta, F. Sallusto

The paper identifies immunodominant and cross-reactive CD4+ T cell epitopes in SARS-CoV-2, showing their recognition in 93% of patients and potential for vaccine design.

bioRxiv · Mar 23, 2021Immunology